STAT+: Novo Nordisk sues Hims & Hers for infringing on a key Wegovy patent

Novo Nordisk has filed a lawsuit against Hims & Hers, a telehealth company, for allegedly infringing on a key patent related to its weight-loss drug, Wegovy. The lawsuit was prompted by Hims & Hers offering a compounded version of Wegovy at a lower price, which Novo Nordisk has described as an “untested knockoff.” The chief counsel of Novo Nordisk has warned that telehealth companies and compounding pharmacies producing similar versions of Wegovy should be “very, very much on notice” regarding the legal implications of their actions (Stat News). In light of the legal challenges and an ongoing investigation by the FDA, Hims & Hers has decided to cease the sale of its compounded weight-loss pill. The company had been marketing this alternative for €41, which attracted significant criticism from Novo Nordisk. The Danish pharmaceutical company has accused Hims & Hers of “illegal mass compounding,” expressing concerns over the safety and efficacy of the unregulated compounded product (Stat News, Euronews). The situation has raised broader concerns within the pharmaceutical and telehealth industries regarding the legality and ethical implications of producing compounded medications that mimic established drugs. Novo Nordisk's actions reflect a strong stance against what it perceives as infringement on its intellectual property and a potential risk to patient safety (Stat News). The outcome of this lawsuit could have significant repercussions for both companies and the compounding pharmacy sector as a whole (Stat News). Hims & Hers' decision to abandon the sale of its copycat weight-loss drug comes amid scrutiny from regulatory bodies, highlighting the challenges faced by companies in the burgeoning telehealth market (Financial Times). The legal battle underscores the tension between established pharmaceutical companies and emerging telehealth providers in the rapidly evolving landscape of weight-loss treatments.